Lexatumumab

Drug Profile

Lexatumumab

Alternative Names: Anti-TRAIL receptor-2 monoclonal antibody; Death receptor 5 monoclonal antibody; DR5 mAB; HGS-ETR2; TRAIL-R2 antibody; TRAIL-R2 human monoclonal antibody; TRAIL-R2 monoclonal antibody

Latest Information Update: 30 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer Human Genome Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 22 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 16 Apr 2008 Human Genome Sciences reacquires rights to lexatumumab from GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top